Evidence map›Paper›PMID 41775867›Full record

ArticleNPJ cardiovascular health2026

Efficacy and safety of Shexiang Tongxin pill for coronary slow flow in angina patients.

Na Li, Zhiqing He, Yasha Chen, Liansheng Wang, Ye Gu, Shenghuang Wang, Yachen Zhang, Min Fan, Bo Yang, Jianjiang Xu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ cardiovascular health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Na Li *Department of Cardiology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Zhiqing He *Department of Cardiology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Yasha Chen *Department of Cardiology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Liansheng WangDepartment of Cardiology, Jiangsu Province Hospital, Jiangsu, China.
Ye GuDepartment of Cardiology, Puai Hospital of Wuhan City, Wuhan, China.
Shenghuang WangDepartment of Cardiology, Ningbo First Hospital, Zhejiang, China.
Yachen ZhangDepartment of Cardiology, Shanghai Xinhua Hospital, Shanghai, China.
Min FanDepartment of Cardiology, Yueyang Hospital of Integrated of Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Bo YangDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
Jianjiang XuDepartment of Cardiology, Jiaxing Second Hospital, Zhejiang, China.
Yansong GuoDepartment of Cardiology, Fujian Province Hospital, Fujian, China.
Yu CaoDepartment of Cardiology, Xiangya Third Hospital of Central South University, Hunan, China.
Wei WangKey Laboratory for Research of Traditional Chinese Medicine Syndrome, School of Pharmaceutics, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. wangwei26960@126.com.
Chun LiangDepartment of Cardiology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China. chunliangliang@126.com.

Funding

Clinical Collaboration Program of Traditional Chinese and Western Medicine for Major and Intractable Diseases ZDYN-2024-A-154National Key R&D Program of China 2022YFC3501701National Natural Science Foundation of China 82120108004, 82574796Shanghai Collaborative Grant for combination of traditional Chinese and Western medicine 2018-2020-FWTX-1102Shanghai foundation for supporting the military and families E3F2A20102Shanghai Wumengchao Medical Science Foundation LCYX20161017-003
6 · The paper itself

Abstract

Previous preclinical studies suggested that Shexiang Tongxin Dropping Pill (STDP) would be effective for coronary slow flow phenomenon (CSFP), but its clinical efficacy and safety remain uncertain. A multicenter, randomized, controlled phase IV trial was implemented to enroll 200 participants diagnosed with angina and CSFP between July 2016 and August 2020 to examine the drug's effectiveness and safety. The analysis revealed that corrected TIMI frame count (CTFC) values in left anterior descending (LAD) and left circumflex (LCX) arteries in STDP group could be decreased, respectively (both p < 0.01), whereas no significant changes were seen with placebo; between group differences were significant for both LAD (p = 0.008) and LCX (p = 0.044). Furthermore, STDP was well tolerated. Taken together, the results demonstrated STDP could significantly improve coronary blood flow and maintain an excellent safety profile, making it a favorable option in clinic for angina patients with CSFP. Trial registration: The trial was registered in Chinese Clinical Trial Registry (ID: ChiCTR-IPR-16008950).

Identifiers

PMID41775867
PMCPMC12912446

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.